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Background and Objectives: Young adults represent an increasingly large proportion
of healthy volunteers in brain imaging research, but descriptions of incidental findings
(IFs) in this age group are scarce. We aimed to assess the prevalence and severity of IFs
on brain MRIs of healthy young research participants aged 18–35 years, and to describe
the protocol implemented to handle them.
Methods: The study population comprised 1,867 participants aged 22.1 ± 2.3 years
(72% women) from MRi-Share, the cross-sectional brain MRI substudy of the i-Share
student cohort. IFs were flagged during the MRI quality control. We estimated the
proportion of participants with IFs [any, requiring medical referral, potentially serious
(PSIFs) as defined in the UK biobank]: overall, by type and severity of the final diagnosis,
as well as the number of IFs.
Results: 78/1,867 participants had at least one IF [4.2%, 95% Confidence Interval (CI)
3.4–5.2%]. IFs requiring medical referral (n = 38) were observed in 36/1,867 participants
(1.9%, 1.4–2.7%), and represented 47.5% of the 80 IFs initially flagged. Referred IFs
were retrospectively classified as PSIFs in 25/1,867 participants (1.3%, 0.9–2.0%),
accounting for 68.4% of anomalies referred (26/38). The most common final diagnosis
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was cysts or ventricular abnormalities in all participants (9/1,867; 0.5%, 0.2–0.9%) and
in those with referred IFs (9/36; 25.0%, 13.6–41.3%), while it was multiple sclerosis or
radiologically isolated syndrome in participants with PSIFs (5/19; 26.3%, 11.5–49.1%)
who represented 0.1% (0.0–0.4%) and 0.2% (0.03–0.5%) of all participants, respectively.
Final diagnoses were considered serious in 11/1,867 participants (0.6%, 0.3–1.1%).
Among participants with referred IFs, 13.9% (5/36) required active intervention, while
50.0% (18/36) were put on clinical surveillance.
Conclusions: In a large brain imaging study of young healthy adults participating in
research we observed a non-negligible frequency of IFs. The etiological pattern differed
from what has been described in older adults.
Keywords: incidental findings, brainMRI, prevalence, young adults, epidemiology,multiple sclerosis, radiologically
isolated syndrome
INTRODUCTION
The widespread use of advanced brain MRI techniques in clinical
research entails increasingly frequent detection of incidental
findings (IFs). An IF is “a finding concerning an individual
research participant that has potential health or reproductive
importance and is discovered in the course of conducting
research, but is beyond the aims of the study” (1). While most
IFs are not clinically meaningful, some can reflect underlying
diseases amenable to treatment or can, in rare instances, be life-
threatening (e.g., aneurysms, neoplasms). In such cases, early
detection and treatment could be of clinical benefit for the
participant. Conversely, detecting and disclosing IFs can entail
increased clinical workload and costs, cause psychological or
financial distress to participants, and expose them to potentially
harmful interventions (1–4). However, specific guidelines on the
identification and management of brain IFs in a research setting
are currently lacking (5–7).
Young adults (18–35 years) participating in biomedical
research represent a particularly challenging group regarding IF
discovery. First, although individuals in this age group represent
a large proportion of “healthy volunteers” in brain imaging
research, descriptions of IFs in this age range are scarce. The very
few available studies were based on small or selected samples with
a broad definition of IFs, low image resolution, and no assessment
of their clinical severity (8, 9). Second, characteristics and severity
of IFs could differ by age (10, 11), with young asymptomatic
adults experiencing greater consequences with longer term effects
than older ones. In this context, a systematic description of the
prevalence and clinical relevance of IFs in young adults could
provide valuable information to notify research participants in
this age range of the likelihood and consequences of IFs.
We sought to assess the prevalence of IFs and their severity
in 1,867 young adults aged 18–35 years, participating in the
MRi-Share brain imaging substudy of the i-Share student cohort,
and to describe the standardized protocol implemented to
manage them.
Abbreviations: IFs, Incidental Findings; PSIFs, Potentially Serious Incidental
Findings; UKB, UK biobank.
MATERIALS AND METHODS
Study Design and Population
The i-Share (internet-based Students’ Health Research
Enterprise) project1 is an ongoing population-based cohort
study of French-speaking students that was launched in 2013
(i) to assess the frequency and impact of various diseases
or conditions affecting young adults, and (ii) to explore the
pathophysiology and early mechanisms underlying common
chronic disorders, including diseases occurring at a later age.
To be eligible, students had to be officially registered at a
University or another higher education institution (HEI), be
at least 18 years of age, and be able to read and understand
French (12). Students were informed about the objectives of the
study through promotion campaigns (flyers, information booths
on admission days, lectures, social media, and newsletters).
Overall, the study was conducted in >420 universities or HEIs
(96% in France), the largest recruitment coming from the
universities of Bordeaux, Versailles-Saint-Quentin-en-Yvelines,
and Nice-Sophia-Antipolis.
The MRi-Share ancillary study is a brain imaging study
embedded within the i-Share cohort, which entails a brain MRI
and a battery of cognitive tests (13). The objectives of MRi-Share
are (i) to characterize morphological and functional variability of
the brain in young adults by building a database of morphological
and functional MRI images, (ii) to describe the anatomical and
functional brain architecture in this population, and (iii) to
characterize brain connectivity and its relation with cognitive
skills. To participate in MRi-Share, i-Share participants had to be
aged between 18 and 35 years, to be registered in a University or
HEI in the Bordeaux area, to have completed the i-Share baseline
self-administered online questionnaire, and signed an informed
consent. Participants with a contraindication to brain MRI (e.g.,
claustrophobia, pacemaker, and other implanted electronic or
metal devices), pregnancy or nursing were not eligible. Between
October 2015 and June 2017, i-Share participants were invited to
take part in MRi-Share. Those interested were then invited for
1i-Share est la plus grande étude scientifique jamais réalisée sur la santé des
jeunes [Internet]. Université de Bordeaux. Available online at: https://www.i-share.
fr (accessed November 24, 2020).
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a visit during which they received detailed information on this
ancillary study and were given a virtual tour of the MRI facility.
Contraindications for the brain MRI were verified and a referent
physician answered any questions they had before signing a
written informed consent. MRi-Share participants received a
compensation of 40 euros.
MRI Protocol
The MRI acquisition protocol for MRi-Share (13) was designed
to emulate that of the UK biobank (UKB) MR imaging study
(14) as much as possible, to enable combined analyses of the
two databases, since early adulthood is currently not covered
by the UKB design. MRIs were performed on a Siemens 3T
Prisma scanner (Erlangen, Germany) with a 64-channel head
coil (gradients: 80 mT/m−200 T/m/s), between November 2015
and November 2017 at the Bordeaux Institute of BIOimaging.
The acquisition lasted about 45min and included the following
five sequences: T1-weighted (T1w) structural imaging (3D
MPRAGE, sagittal acquisition, TR/TE/TI = 2,000/2.0/880ms,
repeat × 2, 1 mm3 isotropic, 192 × 256 × 256); T2-
weighted (T2w) FLAIR structural imaging (3D SPACE, sagittal
acquisition, TR/TE/TI = 5,000/394/1800ms, repeat ×2, 1 mm3
isotropic, 192× 256× 256); Diffusion Weighted Imaging [DWI,
axial acquisition, echoplanar imaging, TR/TE = 3,540/75.0ms,
multiband ×3, 100 directions, multishell b = 0 s/mm2 (8 +
8 phase-encoding reversed), b = 300 s/mm2 (8 directions),
b = 1,000 s/mm2 (32 directions), b = 2,000 s/mm2 (60
directions), 1.75 mm3 isotropic, 118× 118× 84]; Susceptibility-
Weighted Structural Imaging (SWI, axial acquisition, TR/TE1
= 24.0/9.42ms, 0.8 × 0.8 × 3 mm3 anisotropic, 252 ×
288 × 48); and Resting-state functional MRI (2D T2∗-BOLD
resting state, axial acquisition, echoplanar imaging, TR/TE
= 850/35.0ms, multiband × 6, 2.4 mm3 isotropic, 88 ×
88 × 66). A detailed summary of acquisition parameters
for each modality is presented in Supplementary Table 1.
Following the MRI scan, each participant had to complete
a questionnaire about their thoughts while undergoing the
functional MRI and to perform two cognitive tests during
20 min.
Protocol for Assessment and Management
of Incidental Findings
Definitions and Assessment of IFs
This study is focused on IFs identified on structural brain MRI
exclusively. Within days following the MRI acquisition, T1w
and T2w FLAIR images were systematically checked visually
for quality by one of two MD investigators trained in brain
imaging with >30 years’ experience [EM, BM (also professor
of neuroradiology at Bordeaux University Hospital)]. If an IF
(defined as proposed previously) (1) was detected during this
quality control and considered to be potentially harmful for
the participant’s health, it was shown to a specialized clinical
neuroradiologist at Bordeaux University Hospital (TT, professor
of neuroradiology with >12 years’ experience) who checked the
clinical relevance of this IF to decide whether it required medical
referral. DWI and/or SWI images were used to better characterize
IFs detected on T1w and T2w FLAIR. However, raw DWI and/or
SWI images did not undergo visual quality control because those
modalities are prone to artifacts induced by eddy currents and/or
susceptibility effects; efficient quality control of these acquisitions
must be performed after some pre-processing as described
previously (13). Of note, the following IFs were not reported:
(i) T2-hyperintensities that were isolated or in small numbers
(<5), and without any features suggestive of an underlying
inflammatory condition such as ovoid shape and periventricular,
juxtacortical, or posterior fossa location; (ii) small pineal cysts.
For the latter, in the absence of recommendations the threshold
was initially set at 10mm (until May 2016), and subsequently
at 15mm, as the 10mm threshold generated too many cases
and a size >15mm was described to be potentially associated
with neurologic symptoms attributable to mass effect on adjacent
structures or hydrocephalus through the compression of the
cerebral aqueduct (15). All IFs flagged as requiring referral
were reported to a referent neurologist at Bordeaux University
Hospital (SD), and categorized as requiring immediate (e.g.,
acute stroke, encephalitis), urgent (within 1 week, e.g., malignant
brain tumor), or routine medical referral. Prior to consenting to
participate, MRi-Share participants were informed beforehand
that the study might, in rare instances, entail the discovery of
an IF, for which they might be contacted if considered to be
potentially harmful for their health, with detailed information
provided in the setting of amedical visit by a certified neurologist.
i-Share participants volunteering for MRi-Share who refused
to receive feedback about a potential IF were not eligible for
MRi-Share. Participants were also informed that the MRI exam
was not a diagnostic test and that some anomalies might not
be detected.
Disclosure and Handling of Referred IFs
The referent neurologist called the participant <48 h before the
next available neurological outpatient clinic slot, in order to
minimize the period of anxiety and stress. No diagnosis was
given by phone; participants were informed of the presence
of an imaging finding on their MRI scan requiring additional
investigation and an appointment in the outpatient clinic was
organized. In the outpatient clinic, the neurologist explained the
observed abnormality to the participant, collected information
about medical history and ongoing treatments, conducted
a physical examination, and informed the participant about
the proposed follow-up procedures, i.e., additional imaging,
blood tests and/or referral to another physician (if needed
for diagnosis or management purposes, as described in the
letter of information received prior to providing consent).
Psychological support was also proposed at the Student Health
Service center when needed. Following this interview with the
referent neurologist, the participant was systematically invited
to undergo a complementary “clinical” brain imaging (MRI
or CT-scan, with or without contrast enhancement depending
on the nature of the IF), which was interpreted by a clinical
neuroradiologist in the context of clinical care. Once the final
diagnosis was confirmed, the appropriate care was determined
by a specialist on the basis of the type, location, severity, size,
and progression of the IF, as well as clinical symptoms and
medical history.
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Potentially Serious Incidental Findings (PSIFs) and
Severity of Final Diagnosis
In order to facilitate the comparison with published studies,
we retrospectively classified IFs requiring medical referral as
potentially serious incidental findings (PSIFs) using a protocol
developed by the UKB that was not available at the time of our
study (11, 16, 17). First, IFs were defined as PSIFs if listed as
such by the UKB or if meeting their definition of PSIF, i.e., an
IF “indicating the possibility of a condition which, if confirmed,
would carry a real prospect of seriously threatening lifespan, or of
having a substantial effect on major body functions or quality of
life” (17). Finally, for participants with PSIFs who were followed-
up, final diagnoses were considered as “either: serious (if they
were likely to threaten lifespan, or have a substantial impact on
quality of life or major body function); not serious (if this was not
the case or if the diagnosis was already known); or indeterminate
(if there remained insufficient data to classify a final diagnosis as
serious or not)” (11). In participants with more than one PSIF,
the most serious final clinical diagnosis was accounted for.
Other Measurements
Information about sociodemographic and academic
characteristics, health status, personal and family medical
history, and lifestyle habits were collected through the i-Share
baseline self-administered online questionnaire. The following
variables were considered in the analyses to describe the study
sample: age at i-Share inclusion, age at MRI, sex, field of study
(healthcare/health related disciplines vs. others), self-rated health
(defined on a qualitative scale as very good or good vs. fair, bad
or very bad), having visited a physician in the past 12 months,
regular consumption of medications, history of hospitalization
in the past 12 months, familial economic situation during
childhood (rated as very comfortable or comfortable vs. fair,
difficult or very difficult), current sources of income (familial,
scholarship on social grounds, and income-generating activities
during the University year), self-reported physician-diagnosed
migraine, self-reported physician-diagnosed type 1 diabetes,
self-reported physician-diagnosed multiple sclerosis (MS),
family history of stroke or cardiovascular disease (myocardial
infarction, angina pectoris), family history of cancer, being a
current smoker, heavy drinking habits in the past 12 months
[defined as frequent episodes of binge drinking (≥6 drinks
in about 2 h on the same occasion) 2–6 times per week or
every day], use of psychoactive drugs in the past 12 months
(cannabis, ecstasy/3,4 methylenedioxymethamphetamine,
amphetamines, nitrous oxide, inhalant, or cocaine), and use of
other illicit drugs at least once in a lifetime (magic mushrooms
or other hallucinogenic plants, crack/free-base, heroin, LSD,
or ketamine).
Statistical Analyses
To assess whether MRi-Share participants were representative
of i-Share participants at large, we compared characteristics
of i-Share participants recruited at universities or other HEIs
in the Bordeaux area with respect to their participation in
MRi-Share. We first conducted univariate analyses (analysis
of covariance for continuous variables, chi-square or Fisher
exact test for categorical variables). Second, we performed
multivariable logistic regression including all variables associated
with MRi-Share participation in univariate analyses with a
p ≤ 0.05 in the model. Third, we compared MRi-Share
participants’ characteristics according to the presence or absence
of IFs. Finally, we extracted data from radiological and medical
reports to give descriptive statistics: number and proportion
of participants with IFs (any, referred, PSIFs) with their
corresponding 95% Confidence Intervals (CI) when appropriate:
overall, by type of diagnosis and severity; number of IFs.
We also presented the management of IFs. All analyses were
performed using SAS software version 9.4 (SAS Institute Inc.,
Cary, NC, USA), and a two-tailed p ≤ 0.05 was considered
statistically significant.
RESULTS
Of the 14,836 students included in i-Share with a completed
baseline questionnaire at the end of the inclusion period for the
MRi-Share ancillary study, 8,798 were recruited in universities
or other HEIs in Bordeaux or surroundings. Of these, 2,000
FIGURE 1 | MRi-Share flow diagram. *Age criteria not met, n = 4; baseline
questionnaire not completed, n = 1; presence of contra-indications to MRI,
n = 16 (metal fragments or devices, n = 3; claustrophobia, n = 4; others,
n = 9); others, n = 15. †Drop-out, n = 54; study termination, n = 41.
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students responded to the MRi-Share invitation with 1,964
meeting inclusion criteria. After excluding 95 participants for
whom the MRI could not be performed (drop out or termination
of study participation) and two participants who rescinded their
consent, our final MRi-Share study sample comprised 1,867
participants (Figure 1). Baseline characteristics of the 1,867
students included in MRi-Share are presented in Table 1. Our
study population comprised 72% of women with amean age (SD)
at i-Share inclusion and at MRI of 21.2 (2.3) years and 22.1 (2.3)
years, respectively. Among i-Share participants, participation in
the MRi-Share study was associated with older age, healthcare
or health related studies, having had a comfortable or very
comfortable familial economic situation in childhood, having
an income originating from the family or having a scholarship
on social grounds, and use of psychoactive drugs. Migraine and
current smoking were less common in MRi-Share participants
than in i-Share participants who did not take part in the
brain imaging study (multivariable logistic regression analysis,
Table 1).
IFs were detected in 78 of the 1,867 participants (4.2%, 95%
CI: 3.4–5.2%). IFs requiring medical referral (n = 38) were
found in 36 of those 1,867 participants (1.9%, 1.4–2.7%), two
participants having two IFs. Referral was deemed urgent for one
participant (0.05%, 0.0–0.3% of the study sample), and routine
for the others. Twenty six (68.4%) of the 38 IFs referred were
retrospectively characterized as PSIFs [in 25/1,867 individuals





P† OR (95% CI)‡ P‡
(N = 1,867) (N = 6,798)
Age at MRI, years, mean (SD) 22.1 (2.3)
Age at i-Share recruitment, years, mean (SD) 21.2 (2.3) 20.7 (2.8) <0.001 1.07 (1.05–1.09) <0.001
Male Gender 27.8 (519) 24.2 (1,648) 0.002 1.10 (0.97–1.24) 0.14
Field of study
Other 46.2 (861) 71.3 (4,845) <0.001 1.00 <0.001
Healthcare 53.8 (1,002) 28.7 (1,953) 2.68 (2.41–3.00)
Self-rated health
Fair, bad or very bad 17.5 (327) 20.2 (1,371) 0.01 1.00 0.47
Very good or good 82.5 (1,539) 79.8 (5,427) 1.05 (0.92–1.21)
PCP visits 12 months before i-Share inclusion 87.1 (1,626) 86.1 (5,850) 0.23
Regular medication 23.9 (446) 23.1 (1,567) 0.44
Hospitalization 12 months before i-Share inclusion 16.7 (312) 17.5 (1,193) 0.40
Familial economic situation during childhood
Fair, difficult or very difficult 42.0 (783) 49.6 (3,371) <0.001 1.00 0.002
Very comfortable or comfortable 58.0 (1,083) 50.4 (3,427) 1.21 (1.07–1.36)
Source of income
Family 81.8 (1,528) 79.6 (5,412) 0.03 1.20 (1.03–1.39) 0.02
Scholarship on social grounds 37.9 (707) 42.6 (2,899) 0.001 1.16 (1.02–1.31) 0.02
Activities during University year 41.0 (766) 37.0 (2,517) 0.002 1.11 (0.99–1.24) 0.08
Self-reported physician-diagnosed migraine 18.3 (342) 22.9 (1,560) <0.001 0.85 (0.75–0.98) 0.02
Self-reported physician-diagnosed type 1 diabetes 0.4 (8) 0.4 (24) 0.63
Self-reported physician-diagnosed MS 0.1 (1) 0.1 (7) 0.99
Family history of CVD or stroke 14.5 (248) 13.8 (843) 0.45
Family history of cancer 11.5 (203) 11.4 (726) 0.87
Current smoker 29.1 (543) 32.1 (2,181) 0.01 0.81 (0.72–0.93) 0.002
Heavy drinking 12 months before i-Share inclusion 5.1 (92) 4.1 (268) 0.07
Use of psychoactive drugs 12 months before i-Share inclusion§ 47.4 (873) 39.4 (2,623) <0.001 1.44 (1.27–1.62) <0.001
Use of other illicit drugs at least once in a lifetime¶ 3.9 (73) 4.3 (289) 0.49
Data were collected through the baseline i-share questionnaire before the MRI was done. Values are percentages (number) unless stated otherwise. PCP, Primary care physician; MS,
Multiple Sclerosis; CVD, cardiovascular disease.
Heavy drinking in the past 12 months is defined as frequent episodes of binge drinking (≥six drinks in about 2 h on the same occasion) 2–6 times per week or every day.
*Bordeaux i-Share participants included in MRi-Share ancillary study (fulfilling inclusion criteria, with a signed consent), and a valid MRI.
†
Analysis of covariance for continuous variables; chi-square or Fisher exact test for categorical variables.
‡
Odds ratios (OR) and p-values obtained from Multivariable logistic regression models including all variables significantly associated with the participation in MRi-Share in univariate
analyses (with a p ≤ 0.05 in analyses).
§Cannabis, ecstasy/3, 4-Methylenedioxymethamphetamine, amphetamines, nitrous oxide, inhalant, or cocaine.
¶Magic mushrooms or other hallucinogenic plants, crack/free-base, heroin, LSD, or ketamine.
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(1.3%, 0.9–2.0%)]. Indeed, some lesions that in our opinion
required medical referral were not considered as such in the
UKB; moreover, for some lesions that were most likely not
serious, we preferred to formally rule out differential diagnoses or
rare complications by conducting follow-up investigations (e.g.,
brain MRI with contrast enhancement, electroencephalography).
Participants with IFs (any, requiring medical referral, or PSIFs)
did not significantly differ from those without in terms of baseline
characteristics (Table 2).
The procedure for detection and management of IFs
is outlined in Figure 2. Of the 36 participants with IFs
requiring medical referral, 35 (97.2%) were seen by the referent
neurologist, and 33 (91.7%) underwent the recommended
clinical brain imaging (MRI or CT). One participant remained
unreachable after failing to attend the scheduled appointment
with the referent neurologist and another participant refused the
recommended clinical brain imaging. In both cases, the primary
care physician was informed about the IF, with participants’
prior consent. In one participant, the IF was retrospectively
found to have already been diagnosed on a previous clinical
brain MRI prior to MRi-Share participation. In total, 30
out of the 33 (90.9%) participants with a complementary










(N = 1,789) (N = 78) (N = 36) (N = 25)
Age at MRI, years, mean (SD) 22.1 (2.3) 22.2 (2.5) 22.4 (2.6) 22.5 (2.2) 0.79 0.40 0.33
Age at i-Share recruitment, years, mean (SD) 21.2 (2.3) 21.3 (2.7) 21.5 (2.8) 21.8 (2.3) 0.75 0.43 0.23
Complementary brain imaging, median (min, max) 1.0 (0.0–4.0) 1.0 (0.0–4.0)
Visits with medical specialists, median (min, max) 1.0 (0.0–6.0) 2.0 (0.0–6.0)
Male Gender 27.6 (493) 33.3 (26) 22.2 (8) 20.0 (5) 0.27 0.48 0.40
Field of study
Other 46.3 (827) 43.6 (34) 50.0 (18) 44.0 (11) 0.63 0.66 0.82
Healthcare 53.7 (958) 56.4 (44) 50.0 (18) 56.0 (14)
Self-rated health
Fair, bad or very bad 17.5 (313) 17.9 (14) 27.8 (10) 28.0 (7) 0.92 0.11 0.18
Very good or good 82.5 (1,475) 82.1 (64) 72.2 (26) 72.0 (18)
PCP visits 12 months before i-Share inclusion 87.1 (1,558) 87.2 (68) 88.9 (32) 88.0 (22) 0.99 0.76 0.99
Regular medication 24.1 (431) 19.2 (15) 30.6 (11) 36.0 (9) 0.32 0.37 0.17
Hospitalization 12 months before i-Share inclusion 16.5 (295) 21.8 (17) 27.8 (10) 28.0 (7) 0.22 0.07 0.17
Familial economic situation during childhood
Fair, difficult or very difficult 41.7 (746) 47.4 (37) 50.0 (18) 48.0 (12) 0.32 0.32 0.53
Very comfortable or comfortable 58.3 (1,042) 52.6 (41) 50.0 (18) 52.0 (13)
Source of income
Family 81.8 (1,464) 82.1 (64) 77.8 (28) 76.0 (19) 0.96 0.53 0.44
Scholarship on social ground 37.6 (672) 44.9 (35) 47.2 (17) 56.0 (14) 0.19 0.24 0.06
Activities during University year 41.3 (739) 34.6 (27) 38.9 (14) 36.0 (9) 0.24 0.77 0.59
Self-reported physician-diagnosed migraine 18.2 (325) 21.8 (17) 25.0 (9) 28.0 (7) 0.42 0.29 0.20
Self-reported physician-diagnosed type 1 diabetes 0.4 (7) 1.3 (1) 2.8 (1) 4.0 (1) 0.29 0.15 0.11
Self-reported physician-diagnosed MS 0.1 (1) 0.0 (0) 0.0 (0) 0.0 (0) 0.99 0.99 0.91
Family history of CVD or stroke 14.8 (243) 7.2 (5) 9.7 (3) 15.0 (3) 0.08 0.61 0.99
Family history of cancer 11.3 (191) 16.7 (12) 15.2 (5) 22.7 (5) 0.17 0.42 0.10
Current smoker 29.5 (527) 20.5 (16) 22.2 (8) 16.0 (4) 0.09 0.34 0.14
Heavy drinking 12 months before i-Share inclusion 5.1 (88) 5.6 (4) 9.1 (3) 4.3 (1) 0.78 0.24 0.99
Use of psychoactive drugs 12 months before i-Share inclusion|| 47.7 (841) 41.6 (32) 42.9 (15) 37.5 (9) 0.29 0.57 0.32
Use of other illicit drugs at least once in a lifetime** 4.0 (72) 1.3 (1) 2.8 (1) 4.0 (1) 0.37 0.99 0.99
Data were collected through the baseline i-share questionnaire before the MRI was done. Values are percentages (number) unless stated otherwise. PCP, Primary care physician; MS,
Multiple Sclerosis; CVD, cardiovascular disease.
Heavy drinking in the past 12 months is defined as frequent episodes of binge drinking (≥six drinks in about 2 h on the same occasion) 2–6 times per week or every day.
*Bordeaux i-Share participants included in MRi-Share ancillary study (fulfilling inclusion criteria, with a signed consent) and a valid MRI (N = 1,867).
†
PSIFs (Potentially Serious Incidental Findings) are IFs referred that were retrospectively identified according to the list of PSIFs developed by the UK biobank, or its definition of PSIFs.
Analysis of covariance for continuous variables or chi-square/Fisher exact test for categorical variables are used to compare:
‡
participants without IFs vs. those with IFs; §participants
without IFs vs. those with IFs referred; ¶participants without IFs vs. those with PSIFs.
||Cannabis, ecstasy/3, 4-Methylenedioxymethamphetamine, amphetamines, nitrous oxide, inhalant, or cocaine.
**Magic mushrooms or other hallucinogenic plants, crack/free-base, heroin, LSD, or ketamine.
Frontiers in Neurology | www.frontiersin.org 6 May 2021 | Volume 12 | Article 675244
Soumaré et al. Brain IFs in Young Adults
FIGURE 2 | Procedure for detection and management of incidental findings (IFs). MD, medical doctor; PSIFs, potentially serious incidental findings. *Refusal by the
participant, n = 1; not necessary (previous reassuring MRI performed prior to i-Share research MRI), n = 1. †Refusal of follow-up visit, n = 2; not necessary, n = 1.
brain imaging were seen by at least one additional
medical specialist.
Table 3 presents the initial putative diagnosis for the 38
IFs of the 36 participants requiring medical referral. After
additional medical referral and ancillary examinations, the
suspected diagnosis changed for five of the 36 participants
referred (13.8%, Table 3). No conclusion could be drawn on
the final diagnosis for three participants, i.e., the one who
failed to attend the visit with the referent neurologist, the one
who refused the complementary clinical imaging, and one who
underwent the complementary brain MRI but did not attend
additional visits and ancillary examinations requested for an
accurate diagnosis. All participants with an IF seen by the
referent neurologist underwent a thorough clinical interview
to rule out any prior symptoms that could retrospectively
be attributed to the IF. Some were prescribed additional
ancillary investigations, such as an electroencephalography if
the IF was deemed to be a potential source of epilepsy. In
participants with T2 abnormalities suggestive of demyelination
based on their location, size, and morphology, a brain and spinal
cord MRI with gadolinium injection and a lumbar puncture
were performed.
Cysts/ventricular abnormalities were the most frequent
referred IFs in MRi-Share, detected in nine of 1,867 participants
(0.5%, 95% CI: 0.2–0.9% of the study sample), comprising
pineal cysts, arachnoid cysts, and hydrocephalus (Table 3,
Supplementary Table 2). Vascular abnormalities, composed
primarily of cavernomas, were the secondmost common referred
IFs in the study sample, observed in six participants (0.3%, 0.1–
0.7%). They were followed by white matter hyperintensities
suggestive of inflammatory disease observed in five participants
(0.3%, 0.09–0.7%), of whom two were diagnosed with MS (0.1%,
0.0–0.4%) according to the McDonald criteria (18), and three
with Radiologically Isolated Syndrome (RIS) (0.2%, 0.03–0.5%)
based on the Okuda and DIS-Barkhof criteria (19, 20). One of
the two MS patients had initially been diagnosed with a RIS.
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TABLE 3 | Diagnosis’ classification of the 38 incidental findings (IFs) of the 36 participants requiring medical referral according to etiology.
Initial diagnosis on research MRI N Final diagnosis after clinical brain imaging and assessment N
(N = 36 participants) (N = 33 participants)
Cysts/ventricular abn. (n = 9) Pineal cyst 5 Cysts/ventricular abn. (n = 9) Pineal cyst 5
Ventriculomegaly with stenosis of
aqueduct of Sylvius‡
1 Passive hydrocephalus with stenosis
of aqueduct of Sylvius‡§
1
Arachnoid cyst† 3 Arachnoid cyst†§ 2
Arachnoid cyst† 1
Vascular anomaly (n = 7) Cavernoma‡ 4 Vascular anomaly (n = 6) Cavernoma‡§ 4
DVA 2 DVA 2
dPVS*† 1
Inflammatory WMH (n = 12) RIS or MS*‡ 11 Inflammatory WMH (n = 5) MS‡§ 2
Inflammatory leukoencephalopathy*‡ 1 RIS‡¶ 3
Tumors (n = 3) Ependymoma† 1 Tumors (n = 4) Ependymoma†§ 1
MVNT† 2 MVNT†¶ 2
Ganglioglioma†§ 1
Cortical malformations (n = 3) Neuronal migration disorder 2 Cortical malformations (n = 3) Neuronal migration disorder 2
Focal cortical dysplasia‡ 1 Focal cortical dysplasia‡¶ 1
Other, neurological (n = 1) Basal ganglia calcifications‡ 1 Other, neurological (n = 5) Fahr’s syndrome‡¶ 1




Other, non-neurological (n = 3) Hypertrophy lymphoid tissue in cavum 1 Other, non-neurological (n = 3) Hypertrophy lymphoid tissue in cavum 1
Bone lesion 1 Benign bone lesion 1
Lesion or retention in sinus 1 Cyst in sinus 1
abn., abnormalities; DVA, Developmental Venous Anomaly; MVNT, Multinodular and Vacuolating Neuronal Tumor; dPVS, dilated Virchow Robin Space; WMH, White Matter
Hyperintensities; RIS, Radiologically Isolated Syndrome; MS, Multiple Sclerosis. Thirty-four participants referred have one IF; two participants have two IFs.
Initial diagnosis could not be confirmed for three inflammatory WMH suggestive of RIS or MS.
*Initial diagnosis modified after additional medical referral and ancillary examinations: one dPVS (vascular anomaly) turned out to be a ganglioglioma (tumor), three inflammatory WMH
suggestive of RIS or MS turned out to be WMH without underlying inflammatory disease, one inflammatory WMH suggestive of inflammatory leukoencephalopathy turned out to be an
undetermined leukoencephalopathy.
In bold, Potentially Serious Incidental Findings (PSIFs) are IFs referred that were retrospectively identified according to:
†
the list of PSIFs developed by the UK biobank, or
‡
the UK
biobank definition of PSIFs.
Final diagnosis classified as §serious, or ¶ indeterminate, according to the UK biobank definition of diagnosis severity in participants with PSIFs followed-up.
Other IFs included cortical malformations, non-neurological
IFs, and Fahr’s syndrome (Table 3, Supplementary Table 2).
Among participants with PSIFs according to the UKB list
or definition and follow-up available for a final diagnosis
(n = 19), RIS or MS were the most common IFs (26.3%,
Supplementary Table 2). Serious diagnoses, as defined in
the UKB (11), occurred in 11/1,867 participants (0.6%,
0.3–1.1% of total study sample), representing 57.9% (36.2–
76.9%) of participants with PSIFs and a final diagnosis
(11/19) (Table 3). Conversely, non-serious and indeterminate
diagnoses occurred in one (0.05%, 0.0–0.3% of the study
sample) and seven (0.4%, 0.2–0.8% of the study sample)
participants, respectively.
Regarding the management of identified IFs, active
intervention was required for five participants with referred
IFs (also defined as PSIFs) (0.3%, 0.09–0.7% of the study
sample; 13.9%, 5.6–29.1% of participants with referred IFs),
and comprised surgery, medical treatment, or both. Clinical
surveillance with or without follow-up brain imaging was
prescribed for 18 participants with referred IFs (1.0%, 0.6–1.5%
of the study sample; 50.0%, 34.5–65.5% of participants with
referred IFs).
DISCUSSION
In 1,867 young students (aged 18–35 years) who underwent
3T brain MRI as part of their participation in the MRi-
Share research project, IFs were detected overall in 4.2%
(3.4–5.2%) of participants, and IFs requiring medical referral
in 1.9% (1.4–2.7%) of participants. The frequency of PSIFs
according to the UKB list or definition was 1.3% (0.9–2.0%),
while final diagnoses were considered serious in 0.6% (0.3–
1.1%) of the participants. The leading final diagnosis was cysts
or ventricular abnormalities in participants with referred IFs
(25.0%), while it was MS or RIS among those with PSIFs
followed-up (26.3%). In this young student population, the
prevalence of MS and RIS was, respectively, 0.1% (0.0–0.4%)
and 0.2% (0.03–0.5%).
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Comparison With Other Studies and
Implications of Findings
To our knowledge, only two studies have focused on brain IFs
specifically in healthy young adults (8, 9), describing a prevalence
of IFs between 5.8 and 9.4%. In one study (N = 2,536 men,
mean age: 20.5 years) (8), IFs were defined as abnormal findings
based on the sole judgment of one general radiologist. In the
other study (N = 203; mean age: 21.9 years) (9), scans were
read by a neuroradiologist, but IFs could also broadly include
variations of the norm. A subsequent meta-analysis suggested
that the rate of PSIFs in these two studies was in fact lower
than in MRi-Share, between 0.5 and 0.7% (17) vs. 1.3%. Potential
explanations for these differences with MRi-Share findings are
several fold, including differences in sample characteristics, MRI
methodology (1–1.5T vs. 3T MRI and advanced sequences such
as SWI inMRi-Share), and IF definitions. Differences in detection
protocols [single reader—in one case non-specialty (8) vs. two
consecutive subspecialty readers with >12–30 years’ experience
in brain imaging in MRi-Share] can also be highlighted. Indeed,
lesion detection in neuroradiology settings relies on the level of
expertise and experience of the reader, with non-specialty readers
(non-neuroradiologists) performing at lower accuracy compared
with subspecialty ones (neuroradiologists) (21); moreover, blind
double interpretation is supposed to reduce diagnostic errors
in radiology particularly with the added value of a specialist
neuroradiology second opinion vs. a general radiologist (22).
Recently, the UKB assessed the prevalence, type, and final clinical
diagnosis of PSIFs in 7,334 middle-aged and older research
participants (40–69 years; median age: 63 years) (11). MRI
machines (Siemens Prisma) and acquisition parameters were
the same as in MRi-Share by design (13). In the UKB, brain
PSIFs were detected in 58 participants (0.8%, 0.6–1.0%) using
two protocols: a systematic review by a radiologist for the first
1,000 scans (protocol 1, 2.3%), and a radiographer flagging for
confirmation by a radiologist for the subsequent 6,334 scans
(protocol 2, 0.6%). Serious diagnoses occurred in 0.2% (0.1–0.4%)
of the sample (protocol 1, 0.4%; protocol 2, 0.2%) representing
29.3% of those with PSIFs. The slightly higher prevalence of
PSIFs and serious diagnoses in MRi-Share could be due to
differences in the age of participants (althoughmore IFs would be
expected with increasing age) (23), selection bias, and systematic
reading by a neuroradiologist or MD investigators highly trained
in brain imaging and subsequently by a highly trained clinical
neuroradiologist in MRi-Share. Finally, a systematic review
and meta-analysis of 16 neuroimaging studies (N = 19,559
individuals) (24) and an umbrella review of two systematic
reviews (N = 27,316 individuals) (25) reported IF discovery rates
of 2.7 and 22%, respectively. However, these two studies did
not provide any additional results for young adults beyond the
aforementioned studies (8, 9).
While cysts and vascular anomalies were the most common
brain IFs overall in MRi-Share (a quarter of referred IFs),
consistent with prior research in young and pediatric populations
(8, 9, 26), PSIFs and serious IFs were both dominated by
MS or RIS (nearly a quarter of cases). MS and RIS were not
described in middle-aged and older adults from UKB, where
tumors were the dominating PSIFs, mostly of a different type
(meningioma, pituitary tumor, vestibular schwannoma) than
the few tumors seen in MRi-Share (ependymoma, multinodular
and vacuolating neuronal tumor). A similar variation of tumor
histological subtypes by age was recently reported by the Central
Nervous System tumor registry of the Bordeaux (Gironde) region
in France (27).
The relatively high frequency of MS and RIS in this sample
of healthy young adults (0.3% in total, of which 0.2% for RIS) has
important implications.MS is a potentially disabling neurological
disease with a considerable impact on quality of life (28). There is
converging evidence that patients with MS and early initiation
of disease modifying therapy (DMT) have a more favorable
outcome with a lower frequency of clinical attacks. RIS is a
syndrome described for the first time in 2009 and defined by
incident MRI findings typical of MS in persons without a clinical
history of neurological symptoms suggestive of central nervous
system demyelination (20). Despite growing research and clinical
interest in RIS, its epidemiology remains unclear. Data on its
diagnosis in various settings and populations, its natural course,
and predictors are sorely needed. Over half of RIS patients were
recently shown to develop MS over 10 years of follow-up in
the largest international series (29). Whether to treat persons
with RIS using MS DMT is debated and currently assessed in
clinical trials (NCT02739542, NCT03122652), but clinical follow-
up is strongly recommended to initiate treatment early if clinical
symptoms arise. In terms of frequency, a systematic review based
on autopsy studies and clinical registries of MRI data found
a cumulative incidence of RIS of ∼0.1% (30). Hospital-based
studies estimated a prevalence of 0.05% in the broad age group
of 0–90 years (0.15–0.7% in 15–40 years) (31, 32). Another study
that collected data from all imaging centers in a region of Sweden,
over a year, thus reflecting a population-based catchment area,
reported a prevalence of 0.1% among 1,907 individuals aged
0–91 years (33). Because it has been suggested that estimated
prevalence rates of an abnormality within the general population
cannot serve as a meaningful standard against which to interpret
rates of corresponding serious IF in a given sample (4), the need
for data in young healthy adults in a research setting is crucial.
Strengths and Limitations
Strengths of our study include: the large sample size in
an understudied age group; high resolution 3T brain
MRI; systematic screening of all images by a professor of
neuroradiology or MD highly trained in brain imaging studies
followed by a second review by a highly trained clinical
neuroradiologist (in case of IF discovery), all blinded to the
participants’ clinical status, in order to have the best accuracy
in terms of lesion detection while reducing diagnostic errors;
extensive follow-up investigations enabling more accurate
characterization of IFs. The management procedure of IFs was
optimized through consultations with the ethics advisory board
of the i-Share study and additionally reviewed by an independent
ethics adviser.
We acknowledge limitations. First, our study sample is
not representative of all young adults aged 18–35 years in
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the Bordeaux area. Only 45% of young adults pursue higher
education. Moreover, i-Share participants are not representative
of all students, as is the case in all prospective population-
based studies, regardless of the sampling method used, with a
broader participation of women and most likely a selection bias
toward students with an interest in health research. Finally, MRi-
Share participants reported significantly better socioeconomic
conditions than other i-Share participants in the Bordeaux area,
were more often students in the health sector, and older than
i-Share participants not taking part in MRi-Share. A selection
bias of MRi-Share participants toward students with a history of
neurological symptoms cannot be excluded, although compared
to other i-Share participants they tended to more often self-rate
their health as good or very good and less frequently present a
history of migraine. Second, we did not evaluate non-medical
consequences of reporting IFs to study participants. However, we
carefully designed the IF disclosure process to minimize anxiety,
offered psychological support to participants when needed, and
made arrangements withmedical specialists to reduce the waiting
time for follow-up medical visits. The financial impact of IF
disclosure was minimized by the fact that the French public
national health insurance system carries the main financial
burden of medical follow-up. Furthermore, to make up for
costs not covered by the aforementioned system, students could
access complementary private health insurances covered either
by their parents’ health insurance plans or through the purchase
of their own insurance plan at reduced cost. Third, due to its
focus on young adults, MRi-Share lacks participants of middle
and older ages; this prevented us from exploring whether the
prevalence of IFs differed across the adult lifespan through formal
statistical comparisons. Fourth, the protocol we implemented to
detect and manage brain IFs should be considered within the
specific research context of MRi-Share and might not be well-
suited in other settings, e.g., in countries where private healthcare
predominates, or for studies based on much larger samples given
the resources this would require. Guidelines on the management
of IFs are thoroughly needed. The experience described here,
complementing prior studies, will be informative for scientific
societies or expert groups devising such guidelines in the future.
What This Study Adds and Future
Directions
To our knowledge this is the largest study on IFs in young
adults in a research setting and the first that used a standardized
protocol, optimized through consultations with ethics advisors,
with two independent radiological readings of IFs. It is also
the first to report on the management and severity of IFs in
young adults. Moreover, although our results remain primarily
descriptive, as in most of the literature on incidental findings, the
fact that we used the same type of MRI scanner, the same image
acquisition protocol, and the same IF definitions as in the UK
biobank dataset, allows a qualitative comparison of findings.
Our results provide novel insight into the frequency and
severity of precisely defined IFs in young adults, and also shed
new light on the nature of these IFs, which appears to differ
notably from that in older adults. We found that, with MS,
RIS was the most common PSIF observed in young healthy
research participants, thereby highlighting the importance of
ongoing therapeutic trials on the management of RIS. We also
observed that incidentally discovered brain tumors in young
adults participating in research appeared to differ histologically
from those identified in older adults, although no formal
statistical comparisons could be performed.
In the future, our study could be complemented by a more
extensive exploration of risk factors associated with IFs and
their severity in young adults, requiring much larger samples,
and by a formal assessment of differences in prevalence and
etiology between age groups. Guidelines on the detection and
management of IFs would be highly valuable in order to optimize
the way IFs are handled and also reduce inconsistencies between
studies reporting them. In analogy with recommendations on
the management of incidental genetic findings emerging from
sequencing studies in research (34), scientific societies or expert
groups could propose a list of actionable brain MRI IFs requiring
medical referral, ideally with specific recommendations by age
group, considering the different patterns observed across the
adult lifespan and age-specific clinical implications.
CONCLUSION
Our study provides some guidance on the expected frequency
and severity of IFs on brain MRI in young healthy adults
participating in research, an understudied group, and shows
that the etiological pattern of these IFs is distinct from patterns
described in older adults. White matter lesions revealing MS
or RIS were the most common potentially serious IFs detected
in our study. Altogether, our data may inform IF detection
and management protocols in future research studies involving
brain MRIs of young adults. Given the growing frequency of
brain imaging research, with increasingly large samples and
high resolution, our findings also highlight the need for expert
guidelines on brain MRI IFs management.
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